Publisher: Dove Medical Press
Journal: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Subjects: oral glucose tolerance test, immunotherapy, RC581-951, Targets and Therapy [Diabetes, Metabolic Syndrome and Obesity], kynurenine, Short Report, diabetes, Specialties of internal medicine, tryptophan
Svetlana E Nikoulina1, Dietmar Fuchs2, Phillip Moheno11SanRx Pharmaceuticals, Inc, La Jolla, CA, USA; 2Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck, AustriaAbstract: Calcium pterins have been shown to be significant immunotherapeutic agents in models of breast cancer, hepatitis B, and tuberculosis (Bacillus Calmette-Guérin mycobacteria). These compunds modulate the immuno-enzyme indoleamine 2,3-dioxygenase (IDO) and the blood levels of several identified inflammatory cytokines. Recent research into the pathology of diabetes implicates inflammatory factors in the progression of the disease, leading the authors to study its possible control by one of the calcium pterins, dipterinyl calcium pentahydrate (DCP).The investigators tested DCP as a novel therapeutic for type 2 diabetes. Female C57BL/6 J mice with diet-induced obesity were fed a high-fat diet and were administered DCP in 0.4% carboxymethylcellulose for 21 days. Blood glucose was followed during the dosing period, and an oral glucose tolerance test (OGTT) was carried out on day 21. Measurements of plasma indoleamine 2,3-dioxygenase metabolites (tryptophan and kynurenine) and certain cytokines and chemokines were also taken. DCP 7 mg/kg/day reduced OGTT area under the curve (OGTT/AUC) by 50% (P < 0.05). A significant multivariate regression (P = 0.013; R2 = 0.571) of OGTT/AUC was derived from DCP dosage and plasma Trp. Elevated plasma Trp concentration, likely from heterogeneity in diet and/or indoleamine 2,3-dioxygenase activity, was found to correlate with higher OGTT/AUC diabetic measures, possibly via inhibition of histamine degradation. In conclusion, an optimum dose of DCP 7 mg/kg/day significantly improved the OGTT diabetic state in these female diet-induced obese mice.Keywords: diabetes, immunotherapy, oral glucose tolerance test, tryptophan, kynurenine
The results below are discovered through our pilot algorithms. Let us know how we are doing!
- 1. Moheno P, Pfleiderer W, DiPasquale AG, Rheingold AL, Fuchs D. Cytokine and IDO metabolite changes effected by calcium pterin during inhibition of MDA-MB-231 xenograph tumors in nude mice. Int J Pharm. 2008;355(1-2):238-248.
- 2. Moheno P, Morrey J, Fuchs D. Effect of dipterinyl calcium pentahydrate on hepatitis B virus replication in transgenic mice. J Transl Med. 2010;8:32.
- 3. Sakala IG, Blazevic A, Moheno P, Hoft DF. Dipterinyl calcium pentahydrate inhibits intracellular mycobacterial growth in human monocytes via the C-C chemokine MIP-1beta and nitric oxide. Unpublished manuscript; 2011.
- 4. Moheno P, Pfleiderer W, Fuchs D. Plasma cytokine concentration changes induced by the antitumor agents dipterinyl calcium pentahydrate (DCP) and related calcium pterins. Immunobiology. 2009;214(2):135-141.
- 5. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia. 2005;48(6):1038-1050.
- 6. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. 2005;54 Suppl 2: S114-S124.
- 7. Gallou-Kabani C, Vigé A, Gross MS, et al. C57BL/6 J and A/J mice fed a high-fat diet delineate components of metabolic syndrome. Obesity (Silver Spring). 2007;15(8):1996-2005.
- 8. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem. 1997;43(12):2424-2426.
- 9. Smith MJ, Gar rett RH. A heretofore undisclosed cr ux of eosinophilia-myalgia syndrome: compromised histamine degradation. Inflamm Res. 2005;54(11):435-450.
- 10. Gill DS, Barradas MA, Fonseca VA, Dandona P. Plasma histamine concentrations are elevated in patients with diabetes mellitus and peripheral vascular disease. Metabolism. 1989;38(3):243-247.
- 11. Kaufman LD, Philen RM. Tryptophan: current status and future trends for oral administration. Drug Saf. 1993;8(2):89-98.
No related research data.
No similar publications.